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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the efficacy and safety of adding a long-acting muscarinic agonist (LAMA) to any dose of inhaled corticosteroids (ICS)
compared with increasing the dose of ICS for adults whose asthma is not well controlled.
B A C K G R O U N D
Description of the condition
Asthma is a ’common and potentially serious chronic disease’ of
the airways, which causes difficulty breathing due to narrowing of
the airways, thickening of the airway walls and increased mucus
production (GINA 2014). Asthma is recognised as a heteroge-
neous disease, but commonly causes symptoms including ’wheez-
ing, shortness of breath, chest tightness and cough that vary over
time in their occurrence, frequency and intensity’ (GINA 2014).
Around the world and particularly in low- and middle-income
countries, asthma is frequently undiagnosed anduntreated (Global
Asthma Report 2011), and remains a significant cause of avoid-
able morbidity and mortality in developed countries such as the
UK (NRAD 2014), imposing ’a substantial burden on patients,
their family and the community’ (GINA 2014). Recent World
Health Organisation estimates suggest 300 million people are af-
fected worldwide, with direct treatment costs and indirect costs
of lost productivity among the highest for non-communicable
diseases (Global Asthma Report 2011). Prevalence estimates vary,
and changes over time have been linked to various factors includ-
ing air pollution, tobacco legislation, diet, and prevalence of other
atopic diseases (Anderson 2005).
The two broad aims of asthma treatment are to maintain daily
symptom control and prevent acute worsening of symptoms
known as asthma attacks or ’exacerbations’. To achieve this, med-
ication, usually given via an inhaler, is started at the most appro-
priate level based on severity and frequency of symptoms accord-
ing to treatment ’steps’ laid out in guidelines (e.g. GINA 2014).
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Depending on symptom control and frequency of exacerbations
when treatment has been commenced, therapy can be ’stepped up’
by increasing dose or adding medications to recapture control, or
’stepped down’ to maintain patients at the lowest effective therapy
and minimise side-effects.
Description of the intervention
The lowest treatment step in most guidelines is the sole use of a
short-acting bronchodilating inhaler on an as-needed basis (e.g.
salbutamol), which is often sufficient to treat mild or intermit-
tent asthma symptoms. Regular use of low dose inhaled corticos-
teroids is the primary recommended preventer therapy for people
with persistent asthma who remain inadequately controlled on as-
needed medication alone (Step 2, GINA 2014). Regular ICS has
been shown to improve lung function and reduce the need for re-
liever medications (Adams 2008; Adams 2008a). However, some
people with asthma will continue to have symptoms and asthma
attacks on ICS alone and guidelines suggest a range of treatment
options for this group of patients (step 3 and above). Long-act-
ing beta2-agonists (LABA) such as formoterol and salmeterol are
the current preferred add-on therapy at step 3 (Ducharme 2008;
GINA 2014) as they have been shown to have often small but
statistically significant benefits on a range of outcomes over other
treatment options such as increasing ICS dose (Ducharme 2010),
adding theophylline (Tee 2009), or adding a leukotriene receptor
antagonist (Chauhan 2014). Add-on drugs that allow ICS dose
to be kept low are often seen as preferable since prolonged use of
higher doses of ICS carries the risk of serious unwanted effects
including growth retardation in children, decreased bone density,
eye disorders, sleep problems, and anxiety (NICE 2013).
Long-acting muscarinic antagonists (LAMA), a class of drugs with
proven effectiveness in COPD (Karner 2014) are now being con-
sidered as another add-on therapy for adults with asthma requiring
more than ICS alone. Tiotropium, the first LAMA to be licensed
in COPD and themost widely used, has demonstrated added ben-
efits over LABA in terms of the frequency of exacerbations and
hospital admissions for COPD, but not in terms of mortality or
overall hospital admissions (Chong 2012). Evidence for the safety
and efficacy of aclidinium bromide and glycopyrronium bromide,
two LAMA formulations that have recently been licensed for use
in COPD, is emerging but less well established (Ni 2014).
How the intervention might work
Long-acting muscarinic antagonists block receptors of the neu-
rotransmitter acetylcholine on airway smooth muscle, glands
and nerves, preventing muscle contraction and mucus secretion
(Moulton 2011). The action on these receptors helps to alleviate
symptoms of breathlessness, coughing and wheezing that charac-
terise asthma (Lipworth 2014). These characteristics of LAMA
and the overlap in pathophysiology and symptoms of asthma and
COPD (Gosens 2006) have led to their testing in asthma as an
add-on therapy for patients who do not achieve adequate control
from standard-dose ICS alone, thus avoiding prolonged exposure
to higher doses of ICS.
The most commonly reported side effect of LAMA for airways
disease is dry mouth, with others including constipation or diar-
rhoea, cough, and headache (BNF). All LAMA formaintenance of
airways disease are delivered via inhalers, either by powder (Hand-
iHaler, Genuair, Breezhaler) or soft mist delivery (Respimat), and
are not suitable to be used as rescue medication.
In COPD, there is conflicting evidence regarding the safety of
tiotropium delivered via the Respimat device, with one recent ob-
servational study finding it increased the risk of death, particu-
larly cardiac, compared with placebo via the HandiHaler device
(Verhamme 2013). Another large randomised trial including over
17,000 people with COPD found no significant differences in
long-term safety between the two devices (Wise 2013). As yet it is
unclear whether differential safety profiles will be seen in people
with asthma.
Why it is important to do this review
Only one preparation of LAMA (Spiriva Respimat 2.5 mcg) has
been granted aUK license for use in severe asthma alongside LABA
and ICS (eMC 2014). Following their demonstrated efficacy in
COPD (Karner 2014), clinical trials are emerging to test the use
of various LAMA regimens against the existing treatment options
for asthma. One study found that nearly 30 per cent of patients
who were uncontrolled on fluticasone remained so with the guide-
line recommended addition of LABA (Bateman 2004), suggesting
there is a need for additional options for add-on therapy.
It is important to assess the safety of using LAMA add-on to ICS
as an alternative to prolonged use of high doses of ICS that can
have well established and undesirable side effects (NICE 2013).
Alongside three other reviews also in production, this review will
summarise the evidence to guide the possible use of LAMA add-
on as an alternative steroid-sparing agent. The other reviews will
assess 1) LAMA add-on compared with LABA add-on 2) LAMA
add-on compared with no change to ICS dose, and 3) LAMA add-
on as triple therapy with LABA+ICS compared with LABA+ICS
alone.
O B J E C T I V E S
To assess the efficacy and safety of adding a long-acting muscarinic
agonist (LAMA) to any dose of inhaled corticosteroids (ICS) com-
pared with increasing the dose of ICS for adults whose asthma is
not well controlled.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include double-blinded parallel or crossover randomised
controlled trials (RCTs) of at least 12 weeks’ duration. We will
include studies reported as full-text, those published as abstract
only, and unpublished data. The longer-term effects of ICS may
not wash out between treatments in crossover trials, so we will
perform a sensitivity analysis excluding them from the primary
analyses.
We will not exclude studies on the basis of blinding.
Types of participants
We will include adults (18+) whose asthma is not well controlled
on ICS alone. We will exclude trials that include participants with
other chronic respiratory co-morbidities (e.g. chronic obstructive
pulmonary disease, bronchiectasis).
If studies include adults and adolescents or children under 12 and
data are not reported separately, we will include them if the mean
age in both groups is over 18.
Types of interventions
We will include studies randomising participants to receive any
dose of the following LAMA preparations as an add-on to any
dose of ICS:
• Tiotropium (Spiriva Handihaler or Respimat)
• Aclidinium bromide (Eklira Genuair)
• Glycopyrronium bromide (Seebri Breezhaler)
Eligible comparison group participants will be randomised to re-
ceive an increase in ICS dose.
We will include studies that permit the use of short-acting med-
ications, e.g. salbutamol, terbutaline and ipratropium, as reliever
therapy. However, to assess the effect of LAMA on top of ICS
alone, we will exclude trials where:
• a long-acting beta2-agonist (LABA) was given as part of the
randomised treatment (i.e. LAMA+ICS+LABA vs. ICS+LABA)
• participants were required to be taking a LABA to be
included in the trial
• the majority of participants continued treatment with
LABA alongside the randomised treatment
Types of outcome measures
Primary outcomes
1. Exacerbations requiring oral corticosteroids
2. Quality of life (measured on a validated asthma scale, e.g.
Asthma Quality of Life Questionnaire)
3. Any serious adverse events
Secondary outcomes
1. Exacerbations requiring hospitalisation
2. Lung function (in particular, trough FEV1)
3. Asthma Control (measured on a validated scale, e.g.
Asthma Control Questionnaire or Asthma Control Test)
4. Any adverse events
Reporting one or more of the outcomes listed here in the trial is
not an inclusion criterion for the review.
If exacerbations are reported as a composite of more than one
definition (e.g. patients with one of more exacerbation requiring
hospitalisation or ED visit), we will analyse these separately.
Search methods for identification of studies
Electronic searches
We will identify trials from the Cochrane Airways Group’s Spe-
cialisedRegister (CAGR), which ismaintained by the Trials Search
Co-ordinator for the Group. The Register contains trial reports
identified through systematic searches of bibliographic databases
including the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and
PsycINFO, and handsearching of respiratory journals andmeeting
abstracts (please see Appendix 1 for further details). We will search
all records in the CAGR using the search strategy in Appendix 2.
We will also conduct a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and the WHO trials
portal (www.who.int/ictrp/en/). We will search all databases from
their inception to the present, and we will impose no restriction
on language of publication.
Searching other resources
We will check reference lists of all primary studies and review ar-
ticles for additional references. We will search relevant manufac-
turers’ websites for trial information.
We will search for errata or retractions from included studies pub-
lished in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and report the date this was done within the review.
Data collection and analysis
Selection of studies
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Two review authors (KK and DE) will independently screen titles
and abstracts for inclusion of all the potential studies we identify
as a result of the search and code them as ’retrieve’ (eligible or
potentially eligible/unclear) or ’do not retrieve’. We will retrieve
the full-text study reports/publication and two review authors will
independently screen the full-text and identify studies for inclu-
sion, and identify and record reasons for exclusion of the ineligible
studies. We will resolve any disagreement through discussion or,
if required, we will consult a third person (DA or AB). We will
identify and exclude duplicates and collate multiple reports of the
same study so that each study rather than each report is the unit
of interest in the review. We will record the selection process in
sufficient detail to complete a PRISMA flow diagram and ’Char-
acteristics of excluded studies’ table.
Data extraction and management
We will use a data collection form for study characteristics and
outcome data which has been piloted on at least one study in the
review. One review author (KK) will extract study characteristics
from included studies. We will extract the following study char-
acteristics.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (KK and DE) will independently extract out-
come data from included studies. We will note in the ’Character-
istics of included studies’ table if outcome data was not reported
in a usable way. We will resolve disagreements by consensus or by
involving a third person (DA or AB). One review author (KK)
will transfer data into the Review Manager (RevMan) file.We will
double-check that data is entered correctly by comparing the data
presented in the systematic review with the study reports. A sec-
ond review author (DE) will spot-check study characteristics for
accuracy against the trial reports.
Assessment of risk of bias in included studies
Two review authors (KK and DE) will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins).Wewill
resolve any disagreements by discussion or by involving another
author (DA or AB). We will assess the risk of bias according to the
following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or unclear
and provide a quote from the study report together with a justifi-
cation for our judgment in the ’Risk of bias’ table. We will sum-
marise the risk of bias judgements across different studies for each
of the domains listed. We will consider blinding separately for dif-
ferent key outcomes where necessary (e.g. for unblinded outcome
assessment, risk of bias for all-cause mortality may be very differ-
ent than for a patient reported pain scale). Where information on
risk of bias relates to unpublished data or correspondence with a
trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assesment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations in the ’Differences between protocol
and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios and continuous
data as mean difference or standardised mean difference. We will
enter data presented as a scale with a consistent direction of effect.
We will narratively describe skewed data reported as medians and
interquartile ranges. We will analyse data from crossover trials us-
ing generic inverse variance (GIV) and only if double-counting of
participants has been accounted for. If raw data and adjusted anal-
yses (e.g. accounting for baseline differences) are both presented,
we will use the latter.
We will undertake meta-analyses only where meaningful i.e. if the
treatments, participants and the underlying clinical question are
similar enough for pooling to make sense.
Where multiple trial arms are reported in a single trial, we will
include only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) are combined in the
same meta-analysis, we will halve the control group to avoid dou-
ble-counting.
If change from baseline and endpoint scores are available for con-
tinuous data, we will use change from baseline unless the majority
of studies report endpoint scores. If a study reports outcomes at
multiple time-points, we will use the end-of-study measurement.
When an analysis using only participants who completed the trial
and an analysis which imputes data for participants who were ran-
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domised but did not provide endpoint data (e.g. last observation
carried forward) are both available, we will use the latter.
For dichotomous outcomes, we will assume equivalence of treat-
ments if the odds ratio estimate and its 95% confidence intervals
are between the pre-defined arbitrary limits of 0.9 and 1.1.
Unit of analysis issues
For dichotomous outcomes, we will use participants rather than
events as the unit of analysis (i.e. number of adults admitted to
hospital rather than number of admissions per adult). However, if
exacerbations are reported as rate ratios we will analyse them on
this basis.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as abstract
only). Where this is not possible, and the missing data are thought
to introduce serious bias, we will explore the impact of including
such studies in the overall assessment of results using a sensitivity
analysis.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial heterogeneity (e.g.
I2 greater than 30%) we will report it and explore possible causes
by prespecified subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and exam-
ine a funnel plot to explore possible small study and publication
biases.
Data synthesis
We will use a random-effects model for all analyses as we expect
variation in effects due to differences in study populations and
methods. We will perform sensitivity analyses with fixed-effects.
Summary of findings table
We will create a ’Summary of findings’ table to present results for
all of the named outcomes. We will use the five GRADE con-
siderations (study limitations, consistency of effect, imprecision,
indirectness and publication bias) to assess the quality of a body
of evidence as it relates to the studies which contribute data to the
meta-analyses for the prespecified outcomes. We will apply meth-
ods and recommendations described in Section 8.5 and Chapter
12 of theCochraneHandbook for Systematic Reviews of Interventions
(Higgins) using GRADEpro software (Brozek 2008). We will jus-
tify all decisions to down- or up-grade the quality of studies using
footnotes and we will make comments to aid reader’s understand-
ing of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses for the pri-
mary outcomes:
1. Duration of therapy (≤ 6 months, > 6 months)
2. Corticosteroid dose in the control group (according to
GINA 2014-defined low, medium and high cut-offs)
3. Dose and type of LAMA (e.g. tiotropium handihaler 18
mcg, tiotropium respimat 5 mcg)
We will use the formal test for subgroup interactions in Review
Manager (RevMan).
Sensitivity analysis
We plan to carry out sensitivity analyses on the primary outcomes,
excluding the following:
1. Unpublished data
2. Studies at high risk of bias for blinding of participants and
personnel
3. Crossover studies*
*There may be longer term effects of ICS which do not wash
out before a subsequent treatment is started in crossover trials,
especially at higher doses.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search






Hand-searches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards









8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
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11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Adrenal Cortex Hormones
#6 inhal* NEAR (corticosteroid* or steroid* or glucocorticoid*)
#7 beclomethasone* or beclometasone* OR triamcinolone* OR fluticasone* OR budesonide* OR betamethasone* OR flunisolide*
OR ciclesonide* OR mometasone*
#8 ICS:TI,AB
#9 #5 or #6 or #7 or #8




#14 Seebri OR Breezhaler
#15 Aclidinium*
#16 LAS34273





#22 #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21
#23 #4 and #9 and #22
[Note: in search line #1, MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma]
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